ArticleACS chemical biology2017
Coculture of Marine Invertebrate-Associated Bacteria and Interdisciplinary Technologies Enable Biosynthesis and Discovery of a New Antibiotic, Keyicin.
Article in ACS chemical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- When context matters: community and environmental context to elicit natural products.Essays in biochemistry · 2026Review
- Marine-Derived Rare Actinomycetes: Metabolites and Their Biosynthesis.Marine drugs · 2026Review
- Recent strategies and methodological advances for microbial natural product research in the post-genomics era.Archives of microbiology · 2025Review
- "Hyphae Intertwined, Biomolecules Co-Born"-New Polyketides Induction by Co-Culture of the Mangrove Endophytic FungusMarine drugs · 2025Article
- Griseolutein T from Streptomyces seoulensis, newly identified via combined-culture with Tsukamurella pulmonis, as an efficacious therapeutic agent against multidrug-resistant bacteria.The Journal of antibiotics · 2025Article
- Identification of a fungal antibacterial endopeptidase that cleaves peptidoglycan.EMBO reports · 2025Article
- Co-cultivation strategies for natural product discovery from actinomycetes: unlocking silent secondary metabolism with mycolic acid-containing bacteria.World journal of microbiology & biotechnology · 2025Review
- Enzymatic Glycosylation ofBiomolecules · 2025Review
- Strategies for Actinobacteria Isolation, Cultivation, and Metabolite Production that Are Biologically Important.ACS omega · 2025Review
- Stereoselective Approaches to β-Linked 2-Deoxy Sugars.Molecules (Basel, Switzerland) · 2025Review
- Metabolic engineering approaches for the biosynthesis of antibiotics.Microbial cell factories · 2025Review
- Exploring omics strategies for drug discovery fromFrontiers in pharmacology · 2025Review
- The taxonomy ofFrontiers in microbiology · 2025Article
- Manipulation and epigenetic control of silent biosynthetic pathways in actinobacteria.World journal of microbiology & biotechnology · 2024Review
- Article
- Rapid Unambiguous Structure Elucidation of Streptnatamide A, a New Cyclic Peptide Isolated from A Marine-derived Streptomyces sp.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Bioactive Metabolites from Terrestrial and Marine Actinomycetes.Molecules (Basel, Switzerland) · 2023Review
- Combating Antimicrobial Resistance in the Post-Genomic Era: Rapid Antibiotic Discovery.Molecules (Basel, Switzerland) · 2023Review
- Aspergillus co-cultures: A recent insight into their secondary metabolites and microbial interactions.Archives of pharmacal research · 2023Review
- Elicitation for activation of the actinomycete genome's cryptic secondary metabolite gene clusters.RSC advances · 2023Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Advances in genomics and metabolomics have made clear in recent years that microbial biosynthetic capacities on Earth far exceed previous expectations. This is attributable, in part, to the realization that most microbial natural product (NP) producers harbor biosynthetic machineries not readily amenable to classical laboratory fermentation conditions. Such "cryptic" or dormant biosynthetic gene clusters (BGCs) encode for a vast assortment of potentially new antibiotics and, as such, have become extremely attractive targets for activation under controlled laboratory conditions. We report here that coculturing of a Rhodococcus sp. and a Micromonospora sp. affords keyicin, a new and otherwise unattainable bis-nitroglycosylated anthracycline whose mechanism of action (MOA) appears to deviate from those of other anthracyclines. The structure of keyicin was elucidated using high resolution MS and NMR technologies, as well as detailed molecular modeling studies. Sequencing of the keyicin BGC (within the Micromonospora genome) enabled both structural and genomic comparisons to other anthracycline-producing systems informing efforts to characterize keyicin. The new NP was found to be selectively active against Gram-positive bacteria including both Rhodococcus sp. and Mycobacterium sp. E. coli-based chemical genomics studies revealed that keyicin's MOA, in contrast to many other anthracyclines, does not invoke nucleic acid damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.